

## Clinical Cannabis Medicine: References

1. Orens A, et.al. Marijuana equivalency in portion and dosage. Colorado Department of Revenue. 2015. Available at [https://www.colorado.gov/pacific/sites/default/files/MED%20Equivalency\\_Final%2008102015.pdf](https://www.colorado.gov/pacific/sites/default/files/MED%20Equivalency_Final%2008102015.pdf).
2. Healer.com. 2016. Available at <http://healer.com/cannabis-dosing-less-is-usually-more/>
3. Notcutt WG. Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. *Neurotherapeutics*. 2015;12(4):769-777.
4. Health Canada: Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. 2013; Available at <http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php>
5. Madras B. Update of cannabis and its medical use. Review for the 37th session of the WHO Expert Committee on Drug Dependence. Geneva: World Health Organization, 2015; Available at [http://www.who.int/medicines/access/controlledsubstances/6\\_2\\_cannabis\\_update.pdf](http://www.who.int/medicines/access/controlledsubstances/6_2_cannabis_update.pdf)
6. Hall, W. and Solowij, N. Adverse effects of cannabis. *Lancet*. 1998; 352: 1611-1616.
7. Vandrey, R. and Haney, M. Pharmacotherapy for cannabis dependence: how close are we? *CNS.Drugs*. 2009; 23: 543-553.
8. Zammit, S., Moore, T. H., et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. *Br.J.Psychiatry*. 2008; 193: 357-363.
9. De Hert, M., Wampers, M., et al. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. *Schizophr.Res*. 2011; 126: 270-276.

10. Tambaro S, Bortolato M. Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. *Recent patents on CNS drug discovery*. 2012;7(1):25-40.
11. Timpone JG, Wright DJ, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. *AIDS Res Hum Retroviruses*. 1997 Mar 1;13(4):305-15.
12. Beal JE, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *J Pain Symptom Manage*. 1995;10:89-97.
13. Beal JE, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. *J Pain Symptom Manage*. 1997;14:7-14.
14. Abrams DI, et al. Short-term effects of cannabinoids in patients with HIV-1 infection; a randomized, placebo-controlled clinical trial. *Ann Intern Med* 2003;139:258-266.
15. Haney M, et al. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. *Psychopharmacology* 2005;181:170-178.
16. Haney M, et al. Dronabinol and marijuana in HIV-positive marijuana smokers: Caloric intake, mood, and sleep. *J Acquir Immune Defic Syndr*. 2007;45:545-554
17. Riedel G, Fadda P, et al. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. *Br J Pharmacol*. 2009;156(7):1154-66.

18. Manji HK, Quiroz JA, et al. The underlying neurobiology of bipolar disorder. *World Psychiatry*. 2003 Oct;2(3):136-46.
19. Fitzcharles, M. A., Ste-Marie, P. A., et al. Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome. 2012; Available at [http://www.fibromyalgie-sqf.org/2012\\_fm.pdf](http://www.fibromyalgie-sqf.org/2012_fm.pdf)
20. Zhornitsky S, Stip E, et al. Extrapyrarnidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. *Mov Disord*. 2010 Oct 15;25(13):2188-94.
21. Spigelman I: Therapeutic Targeting of Peripheral Cannabinoid Receptors in Inflammatory and Neuropathic Pain States. In *Translational Pain Research: From Mouse to Man*. Edited by: Kruger L, Light AR. Boca Raton, FL: Frontiers in Neuroscience; 2010.
22. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®: Antiemesis Version 2.2015. Fort Washington, PA: National Comprehensive Cancer Network; 2015.
23. Abrams DI, Couey P, et al. Cannabinoid-opioid interaction in chronic pain. *Clin Pharmacol Ther*. 2011 Dec;90(6):844-51.
24. Turcotte D, Le Dorze JA, et al. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. *Expert Opin Pharmacother*. 2010 Jan; 11(1):17-31.
25. Anikwue R, Huffman JW, et al. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. *J Pharmacol Exp Ther*. 2002 Oct;303(1):340-6.
26. Befort K. et al., (2015) *Front Pharmacol*. 6:6.

27. Blake DR, Robson P, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)*. 2006 Jan;45(1):50-2. Epub 2005 Nov 9.
28. Richardson D, Pearson RG, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. *Arthritis Res Ther*. 2008;10(2):R43.
29. Bab I, Zimmer A, Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. *Ann Med*. 2009;41(8):560-7.
30. Sophocleous A, et al. Heavy Cannabis Use Is Associated With Low Bone Mineral Density and an Increased Risk of Fractures. *Am J Med*. 2017;130(2):214-221.
31. Svízenská I, Dubový P, Sulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. *Pharmacol Biochem Behav*. 2008 Oct;90(4):501-11.
32. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. *Pain*. 2004 Dec;112(3):299-306.
33. Wallace MS, Marcotte TD, et al. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. *J Pain*. 2015 Jul;16(7):616-27.
34. Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. *JAMA*. 2015 Jun 23-30;313(24):2474-83.
35. Nurmikko TJ, Serpell MG, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. *Pain*.

2007;133(1-3):210-20.

36. Abrams DI, Jay CA, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology*. 2007 Feb 13;68(7):515-21.
37. Levenson, J., Kay, D., Buysse, D. The Pathophysiology of Insomnia. *Chest*. 2015;147(4), 1179–1192.
38. Acuna-Goycolea, C., et al. CANNABINOIDS EXCITE CIRCADIAN CLOCK NEURONS. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, 2010;30(30), 10061–10066.
39. Schierenbeck, T., et al. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. *Sleep Med*. 2008;12: 381-389. Review.
40. Murillo-Rodríguez E, et al. Potential effects of cannabidiol as a wake-promoting agent. *Curr Neuropharmacol*. 2014 May;12(3):269-72.
41. Fernandez-Ruiz, J. The endocannabinoid system as a target for the treatment of motor dysfunction. *Br.J.Pharmacol*. 2009;156: 1029-1040.
42. Santangelo SL, Tsatsanis K. What is known about autism: genes, brain, and behavior. *Am J Pharmacogenomics*. 2005;5(2):71-92. Review.
43. Samsam M, et al. Pathophysiology of autism spectrum disorders: Revisiting gastrointestinal involvement and immune imbalance. *World Journal of Gastroenterology : WJG*. 2014;20(29):9942-9951.
44. Siniscalco D, et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. *J Autism Dev Disord*.

2013 Nov;43(11):2686-95.

45. Fukuda S, Kohsaka H, et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. *BMC Musculoskelet Disord*. 2014 Aug 12;15:275.
46. Rom S, Persidsky Y. Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation Review. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2013;8(3):608-620.
47. Kaplan BL. The role of CB1 in immune modulation by cannabinoids. *Pharmacol Ther*. 2013 Mar;137(3):365-74.
48. Samson MT, et. al.. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. *J Immunol*. 2003 May 15;170(10):4953-62.
49. McKallip RJ, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. *Blood*. 2002 Jul 15; 100(2):627-34.
50. *Marsicano G, et al., CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003 Oct 3; 302(5642):84-8.*
51. *Rieder SA, et al., Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. 2010 Aug; 215(8):598-605.*
52. *Börner C, et al., Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation. 2007; 14(6):281-6*
53. *Galiègue S, et al., Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 Aug 15; 232(1):54-61.*

54. Pintér A, Cseh D, et al. Autonomic Dysregulation in Multiple Sclerosis. Kleinschnitz C, Meuth S, eds. International Journal of Molecular Sciences. 2015;16(8):16920-16952.
55. Bostwick JM. Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana. Mayo Clinic Proceedings. 2012;87(2):172-186.
56. Osei-Hyiaman D. Endocannabinoid system in cancer cachexia. Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):443-8. Review.
57. Lotfi-Jam, K., et al., Nonpharmacologic Strategies for Managing Common Chemotherapy Adverse Effects: A Systematic Review. Journal of Clinical Oncology 2008; 26(34):5618-5629.
58. PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Cannabis and Cannabinoids. Bethesda, MD: National Cancer Institute. Updated 3/15/2017. Available at <https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq>. Accessed 4/8/2017
59. Zhu LX, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000 Jul 1;165(1):373-80.
60. McKallip R, et al. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005 Mar 15;174(6):3281-9.
61. Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Lett. 2009 Nov 18;285(1):6-12.
62. McAllister SD, et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol. 2005 Aug;74(1):31-40.

63. Bifulco M, et al. Cannabinoids and cancer: pros and cons of an antitumour strategy. *Br J Pharmacol*. 2006 May;148(2):123-35.
64. Cridge B, Rosengren R. Critical appraisal of the potential use of cannabinoids in cancer management. *Cancer Manag Res*. 2013 Aug 30;5:301-13.
65. Guzmán M. Cannabinoids: potential anticancer agents. *Nat Rev Cancer*. 2003 Oct;3(10):745-55. Review.
66. Massa F, et al.: The endogenous cannabinoid system protects against colonic inflammation. *J Clin Invest*. 2004;113(8):1202-9
67. Aviello G, et al. Chemopreventive effect of the non-psychoactive phytocannabinoid cannabidiol on experimental colon cancer. *J Mol Med (Berl)*. 2012 Aug;90(8):925-34.
68. Romano B, Borrelli F, Pagano E, Cascio MG, Pertwee RG, Izzo AA. Inhibition of colon carcinogenesis by a standardized *Cannabis sativa* extract with high content of cannabidiol. *Phytomedicine*. 2014 Apr 15;21(5):631-9.
69. De-Oliveira AC, Ribeiro-Pinto LF, Paumgarten JR. In vitro inhibition of CYP2B1 monooxygenase by beta-myrcene and other monoterpenoid compounds. *Toxicol Lett*. 1997 Jun 16;92(1):39-46
70. Duran M, Pérez E, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. *Br J Clin Pharmacol*. 2010 Nov;70(5):656-63.
71. Noyes R Jr, et al. Analgesic effect of delta-9-tetrahydrocannabinol. *J Clin Pharmacol*. 1975 Feb-Mar;15(2-3):139-43.



72. Portenoy RK, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. *J Pain*. 2012 May;13(5) 438-49.
73. Johnson JR, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. *J Pain Symptom Manage*. 2010 Feb;39(2):167-79.
74. Johnson JR, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. *J Pain Symptom Manage*. 2013 Aug;46(2):207-18.
75. FAQ about RSO. Phoenixtears.ca website. <http://phoenixtears.ca/faq-about-rso/> Updated 2014. Accessed October 4, 2017.
76. Scripture CD, Figg WD. Drug interactions in cancer therapy. *Nat Rev Cancer*. 2006 Jul;6(7):546-58. Review. Erratum in: *Nat Rev Cancer*. 2006 Sep;6(9):741.
77. Chen CS, Lin JT, et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. *Mol Pharmacol*. 2004 May;65(5):1278-85.
78. Torres S, Lorente M et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Mol Cancer Ther*. 2011 Jan;10(1):90-103.
79. Scott KA, Dalglish AG, Liu WM. The combination of cannabidiol and  $\Delta^9$ -tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. *Mol Cancer Ther*. 2014 Dec;13(12):2955-67

80. Jadoon KA, et al., Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. *Diabetes Care*. 2016 Oct;39(10):1777-86.
81. Horváth B, et al. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. *Am J Pathol*. 2012 Feb;180(2):432-42.
82. Toth C, Mawani S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. *Pain*. 2012 Oct;153(10):2073-82.
83. Geurts L, et al. Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxaemia. *PLoS One*. 2013;8(2):e55963.
84. Coskun ZM, Bolkent S. Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with  $\Delta^9$ -THC. *Cell Biochem Funct*. 2014 Oct;32(7):612-9.
85. Abood ME, et al. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. *Neurosci Lett*. 2001 Aug 31;309(3):197-201.
86. Ramírez BG, et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J Neurosci*. 2005 Feb 23;25(8):1904-13.
87. Raman C, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2004

Mar;5(1):33-9.

88. Rossi S, et al. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* 2010;11(1-2):83-90.
89. Hansen HH, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. *J Neurochem.* 2001 Sep;78(6):1415-27.
90. Marsicano G, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. *Science.* 2003 Oct 3; 302(5642):84-8.
91. Zajicek JP, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. *J Neurol Neurosurg Psychiatry.* 2005 Dec;76(12):1664-9.
92. Zajicek JP, et al. MUSEC Research Group.. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. *J Neurol Neurosurg Psychiatry.* 2012 Nov;83(11):1125-32.
93. Fernández O. Advances in the management of multiple sclerosis spasticity: recent clinical trials. *Eur Neurol.* 2014;72 Suppl 1:9-11.
94. Ball S, Vickery J, Hobart J, et al. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Southampton (UK): NIHR Journals Library; 2015 Feb. (Health Technology Assessment, No. 19.12.) Available at: <https://www.ncbi.nlm.nih.gov/books/NBK274260/>
95. Koppel BS, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American

Academy of Neurology. *Neurology*. 2014;82(17):1556-1563.

96. Nguyen CH, et al. THC ( $\Delta^9$ -Tetrahydrocannabinol) Exerts Neuroprotective Effect in Glutamate-affected Murine Primary Mesencephalic Cultures Through Restoring Mitochondrial Membrane Potential and Anti-apoptosis Involving CB(1) Receptor-dependent Mechanism. *Phytother Res*. 2016 Dec;30(12):2044-2052.
97. Koppel BS. Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. *Neurotherapeutics*. 2015;12(4):788-792.
98. Valdeolivas S, et al. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease. *Int J Mol Sci*. 2017 Mar 23;18(4).
99. Pryce G, et al. Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. *J Neuroimmune Pharmacol*. 2015 Jun;10(2):281-92.
100. Zeissler ML, et al. Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. *Oncotarget*. 2016 Jul 19;7(29):46603-46614.
101. Carroll CB, et al.  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. *Neuropathol Appl Neurobiol*. 2012 Oct;38(6):535-47.
102. Chung YC, et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. *J Immunol*. 2011 Dec 15;187(12):6508-17.
103. Freeman RM, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre,

randomised placebo-controlled trial (CAMS-LUTS). *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Nov;17(6):636-41.

104. Cheung, W., Guo, L., and Cordeiro, M. F. Neuroprotection in glaucoma: drug-based approaches. *Optom.Vis.Sci.* 2008;85: 406-416.
105. Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. *Trans Am Ophthalmol Soc.* 2002;100:215-22; discussion 222-4.
106. Jarvinen, T., et al. Cannabinoids in the treatment of glaucoma. *Pharmacol.Ther.* 2002;95: 203-220.
107. Chen, J., et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. *Biochem.Biophys.Res. Commun.* 2005;330: 1062-1067.
108. Song, Z. H., Slowey, C. A. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. *J.Pharmacol.Exp.Ther.* 2000;292: 136-139.
109. Yoles, E., Belkin, M., and Schwartz, M. HU-211, a nonpsychotropic cannabinoid, produces short- and long- term neuroprotection after optic nerve axotomy. *J.Neurotrauma.* 1996;13: 49-57.
110. Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. *World Journal of Gastrointestinal Pharmacology and Therapeutics.* 2016;7(1):5-20.
111. PTSD: National Center for PTSD. US Department of Veterans Affairs website. <http://www.ptsd.va.gov/public/treatment/therapy-med/treatment-ptsd.asp>. Updated August 18, 2017. Accessed October 4, 2017.
112. Gaston, T., et al., "Pharmacology of cannabinoids in the treatment of epilepsy." *Epilepsy & Behavior* 2017;May;70(Pt

B):313-318. Epub 2017 Jan 10. Review.

113. Tzadok M, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. *Seizure*. 2016 Feb;35:41-4.
114. Devinsky O, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*. 2014 Jun;55(6):791-802.
115. Devinsky, Orrin et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. *The Lancet Neurology*. 2015;(3):270 – 278.
116. Jones NA, et al. Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo. *The Journal of Pharmacology and Experimental Therapeutics*. 2010;332(2):569-577.
117. Geffrey AL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. *Epilepsia*. 2015 Aug;56(8):1246-51.
118. Toth, B. I., et al. Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. *J.Invest Dermatol*. 2011;131: 1095-1104.
119. Maccarrone, M., et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor- dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. *J.Biol.Chem*. 2003; 278: 33896-33903.
120. Wilkinson, J. D. and Williamson, E. M. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the

treatment of psoriasis. *J.Dermatol.Sci.* 2007;45: 87-92.

121. Available at <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tourette-Syndrome-Fact-Sheet>
122. Muller-Vahl, K. R., et al. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. *Pharmacopsychiatry.* 2001;34: 19-24.
123. Muller-Vahl, K. R., et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. *J.Clin.Psychiatry.* 2003;64: 459-465.
124. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? *Neuro Endocrinol Lett.* 2004 Feb-Apr;25(1-2):31-9. Review.
125. Williams, S. J., Hartley, J. P., and Graham, J. D. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. *Thorax.* 1976;31: 720-723.
126. Hartley, J. P., Nogrady, S. G., and Seaton, A. Bronchodilator effect of delta1-tetrahydrocannabinol. *Br.J.Clin.Pharmacol.* 1978;5: 523-525.
127. Tashkin, D. P., et al. Subacute effects of heavy marijuana smoking on pulmonary function in healthy men. *N.Engl.J.Med.* 1976; 294: 125-129.
128. Davies, B. H., et al. A trial of oral delta-1-(trans)-tetrahydrocannabinol in reversible airways obstruction. *Thorax.* 1975;30: 80-85.
129. Crawford, W. J. and Merritt, J. C. Effects of tetrahydrocannabinol on arterial and intraocular hypertension.

Int.J.Clin.Pharmacol.Biopharm. 1979;17: 191-196.

130. Pacher, P., Batkai, S., and Kunos, G. Cardiovascular pharmacology of cannabinoids. *Handb.Exp.Pharmacol.* 2005;599-625.
131. Chauchard E, et al. Cannabis withdrawal in patients with and without opioid dependence. *Subst Abus.* 2014;35(3):230-4.
132. Wesson, D. R., Ling, W. (2003). The Clinical Opiate Withdrawal scale (COWS). *J Psychoactive Drugs.* 35(2). 253-9.
133. American Psychiatric Association . *Diagnostic and Statistical Manual of Mental Disorders.* 5th ed. Arlington, DC: American Psychiatric Association; 2013.
134. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. *Drug Alcohol Rev.* 2003 Sep;22(3):309-15.
135. Adamson SJ, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). *Drug Alcohol Depend.* 2010 Jul 1;110(1-2):137-43.
136. Blumentrath C, et al. Cannabinoid hyperemesis and the cyclic vomiting syndrome in adults: recognition, diagnosis, acute and long-term treatment. *Ger Med Sci.* 2017 Mar 21;15:Doc06
137. Allen JH, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. *Gut.* 2004 Nov;53(11):1566-70
138. Dezieck L, et al. Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series. *Clin Toxicol (Phila).* 2017 Sep;55(8):908-913